Introduction
Telomere shortening and telomerase in determining cell replicative potential has received considerable attention in the last few years. While the role of telomerase has been extensively evaluated in solid tumors, the study of its dysregulation in hematological malignancies, such as leukemias and lymphomas has been somewhat hindered because normal hematopoietic cells express varying levels of telomerase activity according to their state of dierentiation and activation (Hiyama et al., 1995; Counter et al., 1995; Chiu et al., 1996; Zhang et al., 1996; Xu et al., 1999) . This obstacle was overcome following the modi®cation of highly sensitive polymerase chain reaction-based telomeric repeat ampli®cation protocol methods that enabled the precise quanti®ca-tion of telomerase activity in normal hematological cells and its malignant counterparts (Wright et al., 1995; Ohyashiki et al., 1996) . In addition,¯uorescence in situ hybridization with peptide nucleic acid (PNA) probes and¯ow cytometry (¯ow-FISH) method made it possible to analyse telomere length and thus the replication history of dierent cell types of cells sorted by FACS (Rufer et al., 1998) . There has also been great progress in stem cell biology in connection with development of a stem cell transplantation (Notaro et al., 1997; Wynn et al., 1998; Allsopp et al., 2001) .
In this review, we examine whether telomere length measurement and telomerase assays should be added to the roster of methods already used by the clinician in patient management of several types of hematologic neoplasias: acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) known as a preleukemic state, chronic myeloid leukemia (CML), as well as lymphoproliferative disorders (LPD), including chronic lymphocytic leukemia (CLL). Since there are indications that antitelomerase therapy may have value in treating hematologic neoplasias, it seems an appropriate time to take a critical yet balanced overview of the state of the ®eld.
Telomere and telomerase in normal hematopoietic cells and their progeny
Normal stem cells of renewal tissues including speci®c hematopoietic cells expressed some telomerase activity, therefore, the diagnostic value of telomerase detection in leukemia and lymphoma patients needs to be evaluated carefully. Similarly, telomerase inhibitors as anti-cancer agents could potentially compromise the target speci®city in hematologic neoplasias. For this reason, we ®rst need to examine recent studies that demonstrate telomerase activity in immortalized telomerase positive cells as well as normal hematopoietic cells, before considering the telomere and telomerase status of leukemias and lymphomas.
Telomerase activity is detected in the G1, S, and G2+M phase of the cell cycle, but is repressed when such cells enter G0 due to growth factor deprivation or dierentiation (Holt et al., 1996; Zhang et al., 1996; Engelhardt et al., 1997) . These observations lead to the important concept that one factor in¯uencing the level of telomerase activity observed in a population of telomerase-competent cells is the fraction of cells in the proliferative compartment. If most of the cells are in G0, telomerase activity will be very low, while if most are dividing the activity will be much higher. Since telomerase activity does not vary during G1, S, and G2+M, the activity in the population of cells may not re¯ect the rate of cell division, but rather the fraction of cells that are cycling .
The second important concept for interpreting the behavior of stem cells is that the presence of telomerase does not necessarily imply stable and thus unchanging telomere length. The initial studies with hematopoietic cells demonstrated that the mean terminal restriction fragments (TRFs) of total nucleated cells from adult bone marrow was shorter than TRFs of the same type of cells isolated from fetal liver and cord blood (Vaziri et al., 1994; Yui et al., 1998) . Short TRFs were found for puri®ed primitive CD34 + CD38 low cells from adult bone marrow compared to those from fetal liver. In peripheral blood cells, telomeres shortening and telomerase activity progressively decreased with aging (Vaziri et al., 1994; Hiyama et al., 1995; Iwama et al., 1998) . These ®ndings support the idea that telomeres also shorten in hematopoietic stem cells (HSCs) during normal replicative aging.
The level of telomerase activity was dierent in human HSCs and their dierentiate progeny (Counter et al., 1995; Hiyama et al., 1995; Chiu et al., 1996; Zhang et al., 1996 , Sakabe et al., 1998 Yui et al., 1998) (Figure 1 ). In contrast to somatic cells that lack telomerase activity, it is clear that many hematopoietic cells are telomerase-competent. Primitive HSCs are likely to be quiescent most of the time and thus the population of cells exhibits a low level of telomerase activity. However, upon stimulation to proliferate, telomerase activity appears to be upregulated in their immediate progeny and may help to slow down the rate of telomere erosion. The more mature cells then become quiescent again and down-regulate telomerase activity. The telomeres of HSCs shorten, probably due to inadequate levels of telomerase activity that slow but do not prevent telomere erosion.
Both T cells and monocyte/B cells in peripheral blood also had low telomerase activity which was elevated when either cell types was cultured with mitogen (Hiyama et al., 1995; Norrback et al., 1996; . The highest in vivo telomerase expression in normal T cells is present in thymus, followed by T cells in the tonsil (Weng et al., 1996; Pan et al., 1997) . The germinal center B-cells also show high telomerase activity (Norrback et al., 1996 (Norrback et al., , 1997 . Thus, telomerase may play a permissive role in T cell and B cell development and in determining the capacity of lymphoid cells for cell division and clonal expansion.
In summary, HSCs and lymphocytes are telomerase competent and mortal. The gradual telomere loss with aging and rapid cycling of HSCs or lymphocytes might contribute to immunosenescence, exhausted hematopoiesis, and increased likelihood of malignant transformation. One interesting clinical aspect of these ®ndings is the future possibility of selectively upregulated telomerase and controlling telomere length in certain cell types in order to achieve a delayed induction of replicative senescence.
Telomeres and telomerase studies in leukemias and lymphomas
Only a few studies have been published regarding telomere length and telomerase activity in hematologic neoplasias and the total number of patients in most diagnostic group is small. The following section summarizes the studies on telomeres and telomerase in hematologic neoplasias. Telomere length was expressed using TRF analysis and telomerase activity was measured using the quantitative telomere repeat ampli®cation protocol (TRAP) assay (Table 1) .
Acute leukemias
In earlier reports, telomerase was positive in most of acute leukemia patients, however detailed information about the level of enzyme activity was unknown (Nilsson et al., 1994; Kim et al., 1994) . After quantitative system of telomerase activity was established, approximately 75% of the patients with acute leukemia showed elevated levels of telomerase activity. Telomere length was generally shortened (Takeuchi et al., 1994; Yamada et al., 1995; Ohyashiki et al., 1997a) . A high level of telomerase activity (more than 10-fold compared to normal hematopoietic cells) was noted in both AML and ALL (Counter et al., 1995; Broccoli et al., 1995; Zhang et al., 1996; Ohyashiki et al., 1997a; Li et al., 2000; Engelhardt et al., 2000) . The expression of hTERT mRNA closely with telomerase activity measured by TRAP assay (Xu et al., 1998; Ohyashiki et al., 2001) . It is likely that the leukemia-derived stem cells express increasing levels of telomerase activity with an increasing fraction of cycling leukemia cells. The level of telomerase activity decreases to normal levels at the remission state and tends to be higher at the relapse phase (Tatematsu et al., 1996; Ohyashiki et al., 1997a , Engelhardt et al., 2000 . Patients with high levels of telomerase activity show signi®cantly poorer prognosis compared to those with low telomerase activity (Ohyashiki et al., 1997a) , indicating that telomerase activity may be a prognostic factor in acute leukemias. Although most of studies regarding the telomere lengths and telomerase levels of leukemia cells have been performed using mononuclear cells obtained from bone marrow or peripheral blood, the comparison of cells at the similar dierentiation stages (e.g. CD34+ cells) will be required in the future.
Of note is that there are increasing numbers of reports dealing with interstitial telomere repeats in translocations of acute leukemias (Hatakeyama et al., 1999; Cuthbert et al., 1999; Busson Le Coniat et al., 2000) . Although the genesis and the functional consequences are still unknown, further characterization of the biological role including jumping translocations would be necessary in elucidating the signi®cance of interstitial telomere repeats in acute leukemias. These interstitial repeats may re¯ect genomic instability and be useful markers for risk stratifying special group of patients.
Myelodysplastic syndrome (MDS)
MDS is a clonal hemopathy characterized by dysplastic features in blood cells. Since approximately 30% of patients show progression into AML, MDS is known as a preleukemic state (Greenberg et al., 1997) . Unlike de novo acute leukemia, a high level of telomerase activity is not common in MDS, although the level of telomerase activity increases in MDS in comparison with normal bone marrow (Ohyashiki et al., 1999; Li et al., 2000) . In fact, variable telomere length has been observed in bone marrow samples with MDS regardless of the percentage of blasts (Ohyashiki et al., 1994; Boultwood et al., 1997) . Since shortened telomere length appears to be related to complex cytogenetic abnormalities (Ohyashiki et al., 1994) , indicating genomic instability and poor prognosis, there is increasing interest of telomere length rather than telomerase activity in MDS prognosis. In addition, telomere position eect in human cells have recently been demonstrated (Baur et al., 2001 ), therefore, silencing of genes near telomeres could be involved in MDS patients with shortened telomeres. Flow-FISH analysis demonstrates that the telomeres of granulocytes are shorter than the age-matched telomere lengths in patients with bone marrow failure syndromes, perhaps as a result of rapid turn over of stem cell . On the basis of these ®ndings, shortened telomere in MDS may re¯ect the mitotic history of stem cells as well as genomic instability. The relationship between telomere dynamics and cytogenetic and molecular abnormalities occurring during the progression of MDS remains an intriguing research ®eld, and could contribute to the development of an International Prognostic Scoring System for MDS (Greenberg et al., 1997) .
Chronic myeloid leukemia (CML)
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia chromosome (Ph) that creates p210 BCR/ABL chimeric protein. Several published studies demonstrate changes of telomere length and telomerase activity between chronic phase (CP) and blastic phase (BP) (Ohyashiki et al., 1997b; Iwama et al., 1997; Boultwood et al., 2000) . In chronic phase, TRFs are generally shorter, however, in a subset of patients we have found TRFs within the normal range. Since the levels of telomerase activity is elevated but not enough to maintain telomere length in the CP, TRFs may re¯ect a proliferate history of leukemia cells which is closely related to disease severity. The sub-fractionation experiment by¯ow-FISH con®rmed that Ph (+) stem cells cycle more actively than their counterparts in normal individuals (Brummendorf et al., 2000) . In the blastic phase, further reduction of TRFs (6.2+1.4 kb in CP vs. 4.5+0.7 kb in BP) is observed. Although these phenomenon are not seen all patients with CML, high levels of telomerase activity are observed in 42.9% of patients with CML-BP, while none of the patients in CP show a high level of telomerase activity (Table 1) .
Lymphoproliferative disorders
In three independent studies on B-CLL shortened telomeres and normal to relatively low levels of telomerase activity in early stage of CLL (0*II, according to the Rai staging system) are observed. This is possibly due to high degree of cell dierentiation and/or high number of G0 cells. The level of telomerase activity tends to be 2 ± 4-fold higher in late stage than those in early stage (Counter et al., 1995; Trentin et al., 1999; Bechter et al., 1999) . The telomerase activity upregulation appears to occur upon a critical reduction in telomere length. Thus the telomere ± telomerase hypothesis of aging and cancer described above is evident in most patients with B-CLL. However, relatively high telomerase activity are found in a subset of early-stage B-CLL with poor prognosis, while patients with low telomerase activity show a favorable prognosis (Trentin et al., 1999) . This indicates that level of telomerase activity at the time of diagnosis appears to be reliable prognostic factor compared to clinical staging in B-CLL.
Telomerase activity in non-Hodgkin's lymphoma (NHL) is rather dicult to evaluate, since puri®ed normal germinal center B-cells seems to have higher activity levels than lymphomas, and tonsils with a follicular hyperplasia exhibit telomerase levels comparable to lymphoma (Norrback et al., 1996) . Telomerase activity with a local immunologic response must therefore be interpreted with caution. With consideration to the above-mentioned point, approximately 50% of B-NHL patients reveal high level of telomerase activity, and high-grade lymphomas exhibit higher levels of telomerase compared to low-grade cases (Norrback et al., 1996; Harada et al., 1999; Ely et al., 2000; Remes et al., 2000) .
In contrast to NHL, a telomerase-independent mechanism for telomere maintenance has been proposed in Hodgkin's disease, even though direct evidence for an altered telomere maintenance pathway was not demonstrated (Brousset et al., 1997 (Brousset et al., , 1998 . For example, a study by Norrback et al. (1996) has demonstrated that the absence of telomerase activity might be due to an eosinophil-derived telomerase inhibitor. In Hodgkin's disease samples without eosinophillia there is low to moderate levels of telomerase activity (Norrback et al., 1998) . These data indicate that NHL as well as Hodgkin's disease is potential target for anti-telomerase therapy.
Interestingly, the presence of integrated human telomeric repeats (TTAGGG) n has currently been reported in some patients with LPD: human herpesvirus-6 (HHV-6) which contain a (TTAGGG) n motif is found to be integrated into telomeric region of host chromosomes in several LPD patients with no signs of active viral infection (Daibata et al., 1999) . Since the biological signi®cance of externally integrated telomeric sequence is uncertain similar to interstitial telomere repeats, the possible role of chromosomally integrated HHV-6 in the pathogenesis of LPD remains to be elucidated.
As described above, one would predict the following patterns for telomere length and telomerase activity in leukemias and lymphomas: prior to cellular immortalization, telomere length should re¯ect the proliferative history of the cell (e.g. how far the disease has progressed). Several studies demonstrate that TRFs might be a good parameter of disease history of CML in the CP, early stage of CLL, and some of the MDS patients. The level of telomerase activity would be highly in¯uenced by the fraction of cells in the proliferative pool. Shortened telomeres and high telomerase activity is generally observed in most acute leukemias, especially relapsed phase, BP of CML, and high-grade lymphomas. This indicates that measurement of telomerase activity might be useful to monitor early relapse and blastic changes. Although alternative lengthening of telomeres (ALT) to provide telomere maintenance might exist in a subset of leukemias and lymphomas, telomere and telomerase assay might be an aid in the diagnosis and prognosis of hematologic neoplasia (Yeager et al., 1999; Guiducci et al., 2001 ).
Anti-telomerase therapy for the hematologic neplasia
The most important issue we should address for antitelomerase therapy for the hematologic neplasia is whether normal hematopoietic stem cells would also be aected by anti-telomerase therapy. It would be predicted that they should be less aected by telomerase inhibition therapy than neoplastic cells which have a higher late of proliferation and in general higher amount of telomerase activity. In addition, since telomeres of normal hematopoietic cells are likely to be longer than those in most advanced leukemias, antitelomerase therapy could be designed to end at a time when the tumor telomeres have completely eroded while normal hematopoietic stem cells still have considerable telomeres remaining. Thus, we believe there is a window of opportunity to inhibit telomerase in cancer cells and cause their death without causing the stem cells to`run out' of telomeres.
Since the mode of action of telomerase inhibitors may require telomeric shortening before inhibition of cell growth or induction of apoptosis, there may be a signi®cant delay in ecacy. Thus telomerase inhibitors may be useful in treating early stage of hematologic neoplasia such as preleukemic state. In advanced leukemia and lymphoma, anti-telomerase would most likely to given to limit the proliferative capacity of neoplastic cells following conventional chemotherapy. Therefore, anti-telomerase therapy might be helpful for in vitro purging of neoplastic cells in stem cell transplantation, as well as killing minimal residual disease of leukemia and lymphoma (Figure 2) .
Recent approaches for targeting telomerase including antisense oligonucleotides, hammerhead ribozymes, small molecules such as G-quadruplex stabilizers, inhibiting the catalytic (hTERT) component, and immunotherapy. These and other might also shed some light on their eects on anti-telomerase therapy for hematologic neoplasias (Bearss et al., 2000) . For example, Tauchi et al. (unpublished data) have demonstrated that inhibition of telomerase using a dominant negative (DN)-hTERT expression vector in BCR/ABL-transformed cells leads to progressive telomere shortening and apoptosis. For control of CML in the CP, ABL speci®c tyrosine kinase inhibitor, STI571 has recently be shown to give a better hope, however, it is not always eective in the BP (Nakajima et al., 2001) . Therefore, a combination therapy of both DN-hTERT and STI571 may provide a basis for attractive therapeutic strategies in treating CML patients. Another hopeful approach is usage of currently identi®ed hTERT-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic lymphocytes (Arai et al., 2001) , since hTERT is linked to a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes (Vonderheide et al., Figure 2 Therapeutic strategies for curing leukemia patients 1999). That may increase the feasibility of immunotherapy for leukemia, even when conventional chemotherapy was not eective. For some still unknown reason there is preliminary data suggesting that normal immune and stem-like cells do not express telomerase antigens on their cell surface while tumor cells do. Thus, there is the possibility that such approaches could have high speci®city and low toxicity (see chapter by Vonderheide this issue).
While there are still concerns, it is important for us to clarify the telomere/telomerase status in patients with various types of hematologic neoplasia and then determine in speci®c pre-clinical tests the most appropriate usage of the anti-telomerase therapy so that they may eventually be moved into clinical trials.
Telomere/telomerase in transplant biology
Several lines of evidence suggest that recipient of stem cell transplantation have shorter telomeres than do their donors (Notaro et al., 1997; Wynn et al., 1998; Shay, 1998; Lee et al., 1999; Akiyama et al., 1998 Akiyama et al., , 2000 . More recent¯ow-FISH analysis demonstrated that telomere loss of monocytes and T lymphocytes accelerated initially, but became comparable to the loss of telomeres in healthy controls from the second year after transplantation (Rufer et al., 2001) . There might be an increased replicative proliferation demand on stem cells at the time of transplantation and during the engraftment phase. Allsopp et al (2001) reported that telomeres shorten during serial transplantation of murine HSCs. These data suggest that additional telomere loss after stem cell transplantation might aect the incidence and/or time of onset of age-related hematologic disorders including secondary malignancies. It may be reasonable to consider whether we can experimentally elongate the telomeres ex vivo in normal hematopoietic cells before transplantation. It would be also informative to test transgenic mice that overexpress murine TERT in HSC to assess whether telomere length is maintained in these mice and what eect this has on the long term transplantation capacity of HSC.
Prospective
Use of telomerized (telomerase-immortalized) HSCs for tissue engineering might be important for treating patients with leukemias and lymphomas. Recently, Thomas et al. (2000) introduced both hTERT and SV40 large T-antigen into bovine adrenal cells and showed that the modi®ed cells maintained telomeric DNA. They have demonstrated a successful transplantation of these rapidly growing engineered bovine adrenocortical cells into an adrenalectomized SCID mouse. Interestingly, the combined introduction of viral oncoproteins together with telomerase did not result in cancer progression. Some promising areas of tissue engineering include rejuvenation of HSCs for improving stem cell transplants or enhancing general immunity for older patients .
One approach of HSC rejuvenation is transient expression of telomerase that may extend the life span of normal HSC. To control gene expression, Cre/lox recombination system may be useful to elongate critically short telomeres as reported in normal human ®broblast (Steinert et al., 2000) . The 38 kDa Cre recombinase from bacteriophage P1 catalyzes sitespeci®c recombination between 34 bp repeats termed loxP. This system has been successfully used in the past decade in a variety of cells for controlling gene expression including retrovirally transferred genes. Using this system, DNA excision from integrated retroviral lox vectors are performed by the use of negative selectable marker genes (Bergemann et al., 1995) . Transient expression of human telomerase may greatly extend the life span of HSC (Figure 3) .
Finally, it is also important to note that much of what we know about telomere biology in human cells is built on many years of outstanding work that was done using model organisms, such as yeast. While there is still a long way to go before we can translate these fundamental advances into clinical implication of human leukemias and lymphomas, telomeres/telomerase are likely to have many applications for diagnosis and treatment in hematologic neoplasia.
